IBS008738 is a potent TAZ activator. IBS008738 stabilizes TAZ, increases the unphosphorylated TAZ level, enhances the association of MyoD with the myogenin promoter, upregulates MyoD-dependent gene transcription, and competes with myostatin in C2C12 cells. IBS008738 enhances myogenesis in C2C12 cells and facilitates muscle repair in a muscle injury model[1][2].
IBS008738 (0, 24, 48, 72 h) enhances TAZ expression, with a peak at 24 h[1].
IBS008738 (10 μM; 0, 24, 72 h) enhances mRNAs of myogenic markers but not of myofusion markers[1].
IBS008738 (10 μM; 24h) enhances mRNAs of IL-10 in C2C12 cells[2].
Western Blot Analysis[1]
| Cell Line: | C2C12 cells |
| Concentration: | |
| Incubation Time: | Treated for 0, 24, 48, 72 h under differentiation conditions after 24 h under growth conditions. |
| Result: | Enhanced TAZ expression, with a peak at 24 h. |
RT-PCR[1]
| Cell Line: | C2C12 cells |
| Concentration: | 10 μM |
| Incubation Time: | 0, 24, 72 h under differentiation |
| Result: | Enhanced mRNAs of myogenic markers but not of myofusion markers. |
IBS008738 (3 nmol) facilitates muscle repair in Cardiotoxin-injected muscles[1].
IBS008738 (30 μM, 100 μL) prevents Dexamethasone-induced muscle atrophy[1].
IBS008738 (100-μL volume of 30 μM; intramuscular injection; immediately and on day 2 after TBI) diminishes the expression of TNF α and IL-6 but increases that of IL-10 mRNAs in muscles of traumatic brain injury (TBI)[2].
| Animal Model: | Six-week-old female BALB/cByJ mice[1] |
| Dosage: | 3 nmol (0.3 μL of 10 mM IBS008738 was diluted in 100 μL of PBS) |
| Administration: | Injected into the tibialis anterior (TA) muscle of mice under anesthesia. |
| Result: | Facilitated muscle repair in Cardiotoxin-injected muscles. |
| Animal Model: | Six-week-old female BALB/cByJ mice[1] |
| Dosage: | 30 μM (100 μL) |
| Administration: | Injected into the tibialis anterior (TA) and gastrocnemius (GM) muscles on days 9, 11, and 13. |
| Result: | Prevented Dexamethasone-induced muscle atrophy. |